Extensive-stage Small Cell Lung Cancer, Lung Cancer
Conditions
Brief summary
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE) has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and the 2-year survival is extremely low. There is no standard maintenance treatment recommendation for ED-SCLC patients after the first-line therapy.Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine,so this clinical trial is designed to investigate the efficacy and safety of apatinib combine with etoposide as maintenance therapy in ED-SCLC patients after first-line chemotherapy in our center.
Interventions
DRUGApatinib, Etoposide
Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
Sponsors
Sichuan Cancer Hospital and Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic diagnosis of extensive-stagesmall cell lung caner(SCLC) ,after first-line therapy * Performance status of 0～2 on the ECOG criteria * Expected survival is above three months * Adequate hematologic (neutrophil count\>=1.5×109/L, hemoglobin\>=80g/L, platelets\>=80×109/L), hepatic function (aspartate transaminase (AST) & alanine transaminase(ALT) =\<upper normal limit(UNL) x2, bilirubin level =\< UNL x 1.5) * Patients have the ability to understand and voluntarily sign the informed consent, and allow adequate follow-up.
Exclusion criteria
* suffered from other tumor within 5 years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder epithelial tumor). * Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction). * Bleeding tendency or coagulation disorders. * Uncontrolled hypertension (systolic pressure\>150 mmHg , or diastolic pressure\> 90 mmHg). * Urine protein≥++, or urine protein in 24 hours≥2.0g. * severe uncured wounds, ulcers or fracture. * Pregnant or breast-feeding. * Patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents). * The researcher believe that the Patient is not suitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 6 months | The first day of treatment to the date that disease progression is reported |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response rate | Time Frame: 3 month | The ratio between the number of responders and number of patients assessable for tumor response. |
| Duration of Response | up to 24 months | Duration of response is defined as time from the date of the first observed hematologic improvement to the date of the first subsequent documented disease progression or relapse |
| Overall survival | up to 24 months | the first day of treatment to death or last survival confirm date |
| Quality of Life (QoL) questionnaire | up to 24 months | in cancer patients and survivors with dermatologic conditions. This is a nontherapeutic and nondiagnostic protocol to obtain quality of life assessments from cancer patients and survivors who have dermatologic conditions, whether related to cancer therapies, or directly related to the primary cancer diagnosis. Data will be collected by using one or more dermatology-specific QoL instruments based on the underlying skin condition/s. |
Countries
China
Contacts
Primary ContactXionghong Cai, Doctor
Outcome results
None listed